NEW YORK , Dec. 4, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global companion diagnostics market size is estimated to grow by USD 28.98 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 36.5% during the forecast period. Rising use of personalized medicine is driving market growth, with a trend towards rising occurrence of breast cancer. However, limited sustainability of smaller vendors poses a challenge. Key market players include Abbott Laboratories, Abnova Corp., Agilent Technologies Inc., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, BioGenex Laboratories Inc., bioMerieux SA, F. Hoffmann La Roche Ltd., Guardant Health Inc., Illumina Inc., Invivoscribe Inc., Liquid Biotech USA Inc., Myriad Genetics Inc., NG Biotech, QIAGEN NV, Quest Diagnostics Inc., Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The Companion Diagnostics Market is experiencing significant growth due to the increasing trend towards personalized medicine in various therapeutic areas, including cancer, cardiovascular diseases, neurological disorders, and infectious diseases. The use of genetic sequencing and genomics in drug development is driving the demand for companion diagnostics. These tests help in identifying biomarkers and selecting the right patient population for specific therapies, such as immunotherapies like CAR T-cell treatment and immunotherapies, including checkpoint inhibitors. Next-generation sequencing (NGS) plays a crucial role in tumor genome analysis, enabling the identification of molecular targets for therapeutic medications. Immunohistochemistry (IHC) is another essential diagnostic tool used in cancer diagnosis and therapy selection. The market is witnessing innovation in the field of personalized medicine, with companies like Gilead Sciences leading the way in developing companion diagnostics for chronic diseases such as lung cancer and hepatitis B. The ongoing clinical trials for SARS-CoV-2 variants and therapeutic medications also present opportunities for the market. The market caters to various therapeutic areas, including cancer, neurological disorders, cardiovascular diseases, and inflammatory diseases. Companion diagnostics provide molecular data to aid in therapy choices, enabling effective disease treatments and improving patient outcomes. The market is expected to continue growing as the demand for personalized medicine and cutting-edge sequencing technologies increases. The incidence of breast cancer in the US is on the rise, particularly among women, due to unhealthy lifestyle choices such as poor diets, lack of physical activity, tobacco use, and excessive alcohol consumption. According to the CDC, approximately 250,000 breast cancer cases are diagnosed annually among women in the US. This increasing number of breast cancer cases leads to a corresponding rise in the number of women undergoing cancer treatment, which includes chemotherapy, hormonal therapy (Arimidex, Aromasin, Evista, Fareston), and radiation. Companion diagnostics play a crucial role in these treatments by helping healthcare providers personalize treatment plans based on individual patient characteristics. With the growing need for accurate and efficient cancer diagnosis and treatment, the demand for companion diagnostics is expected to increase significantly. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges The Companion Diagnostics Market is experiencing significant growth due to the increasing importance of personalized medicine in various therapeutic areas, including cancer, cardiovascular diseases, neurological disorders, and infectious diseases. Drug development in these areas relies heavily on genetic sequencing and genomics to identify biomarkers for patient-selection diagnostic frameworks. Next-generation sequencing (NGS) plays a crucial role in analyzing the tumor genome and identifying mutations for targeted therapies. Cancer treatments, such as CAR T-cell therapy and immunotherapies, require precise diagnosis and monitoring. Immunohistochemistry (IHC) and ISH are essential tools for diagnosing and monitoring cancer, while SARS-CoV-2 variants require quick and accurate diagnostic tests. Reference laboratories play a vital role in providing molecular data for therapy choices, including chemotherapy, radiation treatment, and personalized immunotherapies. The market for companion diagnostics is expanding to include chronic diseases like lung cancer and hereditary sequencing for breast cancer. Medications like Gilead Sciences' therapeutic medications require companion diagnostics for optimal effectiveness. The challenges of drug development and clinical trials necessitate the use of cutting-edge sequencing technologies and personalized medicine approaches. The market for companion diagnostics is poised for growth in various therapeutic areas, including malignant growth treatment, personalized immunotherapies, and inflammatory diseases. The companion diagnostics market is a competitive industry, with major players holding significant market share. New entrants face challenges due to high product development costs and the financial strain of limited capital and small-scale manufacturing. Established players, however, are well-positioned, continually innovating and expanding their manufacturing facilities globally, particularly in developing countries. These strategic moves enable them to offer advanced, efficient, and safer companion diagnostics to meet growing demand. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This companion diagnostics market report extensively covers market segmentation by 1.1 Life science 1.2 Health centers 1.3 Others 2.1 Oncology 2.2 Neurology 2.3 Others 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Life science- The Companion Diagnostics Market is witnessing significant growth due to the increasing need for pharmaceutical and biotechnology companies to develop high-quality, regulatorily compliant drugs and therapeutic treatments. During the drug discovery process, companion diagnostic products are utilized in the preclinical and clinical stages to evaluate drug response biomarkers, toxicity, and immunotherapy response. These diagnostics play a crucial role in drug discovery by testing multiple targets in a single reaction, reducing the number of samples and hands-on time required, and generating comprehensive data about each analyte of interest. With the high cost of developing and commercializing drugs (over USD2 billion ), pharmaceutical and biotechnology companies cannot afford losses if a drug fails. Companion diagnostics help determine the elemental composition and impurity quantification, minimizing drug failures. The prime goal is to accelerate the drug discovery process by screening compound libraries for drug lead identification and optimization. Partnerships with contract research organizations (CROs) and medical device manufacturers are also driving the adoption of companion diagnostics. These factors are expected to fuel the growth of the life science segment of the global Companion Diagnostics Market throughout the forecast period. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Companion Diagnostics Market is a rapidly growing sector in the healthcare industry, focused on developing diagnostic tests that help select the most effective therapy choices for patients based on their molecular data. These tests play a crucial role in drug development, particularly in cancer treatment, where genetic sequencing and genomics are used to identify biomarkers and patient-selection diagnostic frameworks. Next-generation sequencing (NGS) is a cutting-edge technology used to analyze a patient's tumor genome, enabling the development of targeted therapeutic medications, including immunotherapies like CAR T-cell therapy. The market spans various disease areas, including cancer, chronic diseases such as neurological disorders and cardiovascular diseases, and hereditary sequencing. Companies in this market provide patient-choice diagnostic systems, helping ensure that patients receive the most appropriate disease treatments based on their unique molecular profiles. Market Research Overview The Companion Diagnostics Market refers to in vitro diagnostic tests that are designed to identify specific biomarkers or genetic mutations in patients, guiding therapy choices for effective disease treatments. These tests play a crucial role in drug development, particularly in cancer, where they aid in patient selection using diagnostic frameworks based on molecular data from tumor genomes. Technologies such as next-generation sequencing (NGS), immunohistochemistry (IHC), and hereditary sequencing are used to identify biomarkers in various therapeutic areas, including cancer, neurological diseases, cardiovascular diseases (CVDs), and infectious diseases. Companion diagnostics are essential for personalized medicine, enabling the selection of targeted therapeutic medications, such as immunotherapies like CAR T-cell therapy, and traditional treatments like chemotherapy and radiation. In the context of cancer, these tests are critical for guiding therapy choices for malignant growth treatments, including immunotherapies and targeted therapies. In the era of personalized medicine, companion diagnostics are becoming increasingly important for selecting the most effective therapy for each patient, based on their unique genetic makeup and disease characteristics. The market for companion diagnostics is expected to grow significantly due to the increasing focus on personalized medicine, the development of cutting-edge sequencing technologies, and the expanding range of therapeutic areas, including cancer, neurological disorders, cardiovascular diseases, and inflammatory diseases. The market also includes reference laboratories and biotechnology companies that specialize in the development and commercialization of companion diagnostics. In the context of cancer, companion diagnostics are playing a pivotal role in the development of new therapies, such as immunotherapies and targeted therapies, and are essential for guiding therapy choices for patients with various types of cancer, including breast cancer, lung cancer, and others. The ongoing COVID-19 pandemic has also highlighted the importance of companion diagnostics in the development of therapeutic medications for SARS-CoV-2 and identifying variants of the virus. Overall, the companion diagnostics market is a dynamic and rapidly evolving field, driven by advances in genomics, biomarker discovery, and personalized medicine. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation End-user Life Science Health Centers Others Indication Oncology Neurology Others Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio
HE the Prime Minister and Minister of Foreign Affairs Sheikh Mohammed bin Abdulrahman bin Jassim al-Thani met Friday with the visiting US National Security Adviser Jake Sullivan. The two sides discussed the strategic relationship between the two countries, ways to strengthen and support it, as well as the latest developments in Gaza and occupied Palestinian territories, and the situation in Syria. They also addressed other topics of joint interest. Both parties stressed the importance of ensuring Syria’s unity and pursuing a peaceful transition of power through an inclusive political process based on UN Security Council Resolution 2254, while enhancing efforts to protect civilians and combat terrorism. Related Story New Syria PM says all religious groups' rights 'guaranteed' Blinken on Syria crisis tour with eye on Biden legacy
Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
Aston Villa march on in Champions League after beating RB Leipzig
New study explores financing green hydrogen ironmaking in emerging economies – SEI
AP Trending SummaryBrief at 6:29 p.m. ESTAston Villa march on in Champions League after beating RB LeipzigLegendary singer-songwriter Elton John has said he had to delay the release of his upcoming album due to an eye infection that has significantly impaired his vision. Speaking on ABC’s Good Morning America on Monday, the 77-year-old said he has not been able to see out of his right eye for four months, impacting his ability to work. Elton John lost sight in his right eye following a severe eye infection. Credit: AP “I unfortunately lost my eyesight in my right eye in July because I had an infection in the South of France ... And my left eye’s not the greatest,” he said. “I’m kind of stuck at the moment because I can do something like this [interview], but going into the studio and recording, I don’t know because I can’t see a lyric for a start.” During a speech at the Rock ‘n’ Roll Hall of Fame ceremony last year, John revealed he had a new album on the way with lyricist Bernie Taupin. It would mark his first studio album including all original material since Wonderful Crazy Night in 2016. However, his eye infection has delayed its release. “It’s never fortunate for anything like this to happen, and it kind of floored me. I can’t see anything, I can’t read anything, I can’t watch anything,” John said. The pop star is undergoing unspecified treatment and remains optimistic he will recover. “There’s hope and encouragement that it will be OK. At the moment, that’s really what we’re concentrating on.” The interview comes almost three months after he told fans on social media that he had contracted a severe eye infection that left him with limited sight in the impacted eye. “I am healing, but it’s an extremely slow process,” he wrote on Instagram in September. Despite his impaired vision, John has made multiple appearances over the past few months, including joining pop star Dua Lipa on stage at her Royal Albert Hall concert in October, where they performed their popular duet Cold Heart . Loading The EGOT winner, who retired from touring last year, also attended the premiere of his new Disney+ documentary, Elton John: Never Too Late , in both London and Toronto. Directed by R.J. Cutler and David Furnish, the documentary tracks John’s 50-year career, as he prepared for his final concert at the Dodger Stadium in the US. “I’m so proud of the documentary. I’m proud of my sons. I’m proud of my attitude toward myself and what’s going on,” he said. “I’m just very lucky and I’m very grateful.” John became an EGOT winner at the 2023 Emmy Awards in January after winning the Outstanding Variety Special (Live) category. However, he was unable to attend as he was recovering from knee replacement surgery, which he underwent at the beginning of the year. He had a second knee replacement on his other knee in March. “To be honest with you, there’s not much of me left,” he joked while at a screening of his documentary at the New York Film Festival in October. Find out the next TV, streaming series and movies to add to your must-sees. Get The Watchlist delivered every Thursday . Save Log in , register or subscribe to save articles for later. License this article Live music Elton John Nell Geraets is a Culture and Lifestyle reporter at The Age and The Sydney Morning Herald. Connect via Twitter or email . Most Viewed in Culture Loading
After-hours movers: SentinelOne, Synopsys, PVH Corp, Verint Systems, American EagleNominations Open for 2025 Defense IT Summit Flywheel AwardsJAMAICA, N.Y. , Dec. 13, 2024 /PRNewswire/ -- The New Terminal One at John F. Kennedy International Airport (JFK) today announced that Turkish Airlines will begin operations at the new terminal when it opens in 2026. Turkish Airlines will also unveil a brand new, state-of-the-art lounge for its premium customers, launching the next phase of the award-winning airline's growth at its top U.S. gateway. The New Terminal One, set to be the largest international terminal in the United States , will offer best-in-class amenities and innovative technology for a transformational and efficient travel experience. The New Terminal One is a key component of the Port Authority of New York and New Jersey's $19 billion transformation of JFK Airport into a world-class gateway, which will include two new terminals, the modernization and expansion of two existing terminals, a new ground transportation center, and an entirely new, simplified roadway network. Turkish Airlines, which currently flies 19 times weekly from JFK Airport to its hub at Istanbul , providing seamless connections to its extensive global network, will continue to offer top-tier service from the new terminal. As part of its expansion in the JFK market, Turkish Airlines will open an 11,000-square-foot lounge in the New Terminal One – twice the size of the airline's lounge at the existing Terminal 1. The new lounge will feature premium amenities, expansive views of JFK Airport's airfield and provide direct boarding access to aircraft, offering unmatched convenience for Turkish Airlines' business class customers and top-tier frequent flyers. Recognized for its exceptional in-flight service, Turkish Airlines recently received the World Class Award from the Airline Passenger Experience Association (APEX) for the fourth consecutive year, placing it among just 10 airlines in the world to have received this prestigious recognition. Turkish Airlines was also chosen as the Best Airline in Europe nine times by Skytrax. Over the years Turkish Airlines also received accolades from Skytrax and other prestigious organizations numerous times for its Business and Economy Class offerings and Lounges. Turkish Airlines offers service to 351 destinations, including 25 in the Americas. Turkish is a member of the Star Alliance and will join other alliance members at the New Terminal One: LOT Polish Airlines, EVA Air and Air China. "We are thrilled to welcome Turkish Airlines to the New Terminal One at JFK, where their commitment to world-class customer service aligns perfectly with our mission to provide an unparalleled customer experience," said The New Terminal One Chief Executive Officer Jennifer Aument . "We look forward to working closely with our colleagues at Turkish Airlines to elevate the travel experience for customers from 2026 and beyond." Turkish Airlines Chairman of the Board and the Executive Committee Prof. Ahmet Bolat stated: "We are excited to bring Turkish Airlines' world-class service to the New Terminal One at JFK, further enhancing our passengers' travel experience with a state-of-the-art-lounge. This move underlines our commitment to continue our growth in the U.S market." In addition to Turkish Airlines, the New Terminal One has partnered with several other global carriers, including Air France, KLM, Etihad, LOT Polish Airlines, Korean Air, EVA Air, Air Serbia, SAS, Neos and Philippine Airlines. Air China is also partnering with the terminal on elevating the travel experience for Chinese customers visiting New York . The New Terminal One is focused on improving the customer experience by collaborating with potential airline partners. This includes working with airline teams across all customer journey touchpoints. Set to be JFK Airport's largest terminal when complete, the New Terminal One will offer a world-class customer experience and additional widebody aircraft gate capacity – providing international airlines a unique opportunity to grow their service at JFK, the top global gateway to the U.S. About The New Terminal One The New Terminal One at John F. Kennedy International Airport is a bold and exciting project to develop a world-class international terminal that will serve as an anchor terminal in the Port Authority's $19 billion transformation of JFK into a global gateway to the New York metropolitan area and the United States . The New Terminal One will set a new standard for design and service, aspiring to obtain a Top 5 Skytrax ranking and be considered one of the finest airport terminals in the world. The New Terminal One is being built on sites now occupied by Terminal 1 and the former Terminal 2 and Terminal 3, where it will anchor JFK's south side. Construction is taking place in phases. The first phase, including the new arrivals and departures halls and first set of 14 new gates, is expected to open in 2026. At completion, anticipated in 2030, the New Terminal One will be 2.6 million square feet, making it the largest terminal at JFK and nearly the same size as LaGuardia Airport's two new terminals combined. The New Terminal One will be a 23-gate, state-of-the-art, international-only terminal. Sustainably designed and future-focused, the terminal will feature expansive, naturally lit public spaces, cutting-edge technology, and an array of amenities, all designed to enhance the customer experience and compete with some of the highest-rated airport terminals in the world. The New Terminal One consortium of labor, operating, and financial partners is led by Ferrovial, JLC Infrastructure, Ullico, and Carlyle. The New Terminal One is being built by union labor and is committed to local inclusion and labor participation, focusing on diversity and capacity-building opportunities, including ambitious participation goals of 30% for minority and women-owned enterprises, 10% for local business enterprises and 3% for service-disabled veteran-owned businesses. To learn more about the New Terminal One at JFK International Airport, visit https://www.anewjfk.com/projects/the-new-terminal-one/ About Turkish Airlines Established in 1933 with a fleet of five aircraft, Star Alliance member Turkish Airlines has a fleet of 491 (passenger and cargo) aircraft flying to 351 worldwide destinations in 130 countries (298 international destinations and 53 domestic destinations within Turkiye). More information about Turkish Airlines can be found on its official website www.turkishairlines.com or its social media accounts on Facebook, X, YouTube, LinkedIn and Instagram. View original content to download multimedia: https://www.prnewswire.com/news-releases/turkish-airlines-to-begin-operations-at-the-new-terminal-one-at-jfk-and-unveil-world-class-lounge-302331710.html SOURCE The New Terminal One at JFK
EFCC arrests man for allegedly defrauding 139 AustraliansNEW ORLEANS (AP) — The largest artificial intelligence data center ever built by Facebook’s parent company Meta is coming to northeast Louisiana, the company said Wednesday, bringing hopes that the $10 billion facility will transform an economically neglected corner of the state. Republican Gov. Jeff Landry called it “game-changing” for his state's expanding tech sector, yet some environmental groups have raised concerns over the center's reliance on fossil fuels — and whether the plans for new natural gas power to support it could lead to higher energy bills in the future for Louisiana residents. Meanwhile, Elon Musk's AI startup, xAI, is expanding its existing supercomputer project in Memphis, Tennessee, the city's chamber of commerce said Wednesday. The chamber also said that Nvidia, Dell, and Supermicro Computer will be “establishing operations in Memphis,” without offering further details. Louisiana is among a growing number of states offering tax credits and other incentives to lure big tech firms seeking sites for energy-intensive data centers. The U.S. Commerce Department found that there aren’t enough data centers in the U.S. to meet the rising AI-fueled demand, which is projected to grow by 9% each year through 2030, citing industry reports. Meta anticipates its Louisiana data center will create 500 operational jobs and 5,000 temporary construction jobs, said Kevin Janda, director of data center strategy. At 4 million square feet (370,000 square meters), it will be the company's largest AI data center to date, he added. “We want to make sure we are having a positive impact on the local level,” Janda said. Congressional leaders and local representatives from across the political spectrum heralded the Meta facility as a boon for Richland parish, a rural part of Louisiana with a population of 20,000 historically reliant on agriculture. About one in four residents are considered to live in poverty and the parish has an employment rate below 50%, according to the U.S. census data. Meta plans to invest $200 million into road and water infrastructure improvements for the parish to offset its water usage. The facility is expected to be completed in 2030. Entergy, one of the nation's largest utility providers, is fast-tracking plans to build three natural gas power plants in Louisiana capable of generating 2,262 megawatts for Meta's data center over a 15-year period — nearly one-tenth of Entergy's existing energy capacity across four states. The Louisiana Public Service Commission is weighing Entergy's proposal as some environmental groups have opposed locking the state into more fossil fuel-based energy infrastructure. Meta said it plans to help bring 1,500 megawatts of renewable energy onto the grid in the future. Louisiana residents may ultimately end up with rate increases to pay off the cost of operating these natural gas power plants when Meta's contract with Entergy expires, said Jessica Hendricks, state policy director for the Alliance for Affordable Energy, a Louisiana-based nonprofit advocating for energy consumers. “There’s no reason why residential customers in Louisiana need to pay for a power plant for energy that they’re not going to use," Hendricks said. "And we want to make sure that there’s safeguards in place.” Public service commissioner Foster Campbell, representing northeast Louisiana, said he does not believe the data center will increase rates for Louisiana residents and views it as vital for his region. “It’s going in one of the most needed places in Louisiana and maybe one of the most needed places in the United States of America,” Foster said. “I’m for it 100%.” Environmental groups have also warned of the pollution generated by Musk's AI data center in Memphis. The Southern Environmental Law Center, among others, says the supercomputer could strain the power grid, prompting attention from the Environmental Protection Agency. Eighteen gas turbines currently running at xAI’s south Memphis facility are significant sources of ground-level ozone, better known as smog, the group said. Patrick Anderson, an attorney at the law center, said xAI has operated with “a stunning lack of transparency” in developing its South Memphis facility, which is located near predominantly Black neighborhoods that have long dealt with pollution and health risks from factories and other industrial sites. “Memphians deserve to know how xAI will affect them,” he said, “and should have a seat at the table when these decisions are being made.” Sainz reported from Memphis, Tennessee. Associated Press writer Matt O’Brien in Providence, Rhode Island, contributed to this report. Brook is a corps member for The Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues. Follow Brook on the social platform X: @jack_brook96
Supreme Court seems likely to uphold Tennessee's ban on treatments for transgender minorsTMC Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ...
A fugitive gains fame in New Orleans eluding dart guns and netsFEATURED: Equity Group, DEG launch German Desk to boost East African tradeBy KEVIN FREKING WASHINGTON (AP) — House Republicans teed up a vote this week on bipartisan legislation to gradually expand by 66 the number of federal judgeships across the country. Democrats, though, are having second thoughts now that President-elect Donald Trump has won a second term. The White House said Tuesday that if President Joe Biden were presented with the bill, he would veto it. A Congress closely divided along party lines would be unlikely to overturn a veto, likely dooming the bill’s chances this year. It’s an abrupt reversal for legislation that the Senate passed unanimously in August. But the GOP-led House waited until after the election to act on the measure, which spreads out the establishment of the new district judgeships over about a decade to give three presidential administrations the chance to appoint the new judges. Rep. Jerry Nadler, D-N.Y., said the bill was negotiated with the understanding that three unknown, future presidents would have the chance to expand and shape the judiciary. No party would be knowingly given an advantage. He said he begged GOP leadership to take up the measure before the presidential election. But they did not do so. “It was a fair fight and they wanted no part of it,” Nadler said. Rep. Jim Jordan, the Republican chairman of the House Judiciary Committee, explained the timing this way: “We just didn’t get to the legislation.” The change of heart about the bill from some Democrats and the new urgency from House Republicans for considering it underscores the contentious politics that surrounded federal judicial vacancies. Senate roll-call votes are required for almost every judicial nominee these days, and most votes for the Supreme Court and appellate courts are now decided largely along party lines. Lawmakers are generally hesitant to hand presidents from the opposing party new opportunities to shape the judiciary. Related Articles National Politics | Trump lawyers and aide hit with 10 additional felony charges in Wisconsin over 2020 fake electors National Politics | After withdrawing as attorney general nominee, Matt Gaetz lands a talk show on OANN television National Politics | What will happen to Social Security under Trump’s tax plan? National Politics | Republican-led states are rolling out plans that could aid Trump’s mass deportation effort National Politics | Trump promises to end birthright citizenship: What is it and could he do it? Nadler said that the bill would give Trump 25 judicial nominations on top of the 100-plus spots that are expected to open up over the next four years. “Donald Trump has made clear that he intends to expand the power of the presidency and giving him 25 new judges to appoint gives him one more tool at his disposal to do that,” Nadler said. Nadler said he’s willing to take up comparable legislation in the years ahead and give the additional judicial appointments to “unknown presidents yet to come,” but until then, he was urging colleagues to vote against the bill. Still, few are arguing against the merits. Congress last authorized a new district judgeship more than 20 years ago, while the number of cases being filed continues to increase with litigants often waiting years for a resolution. “I used to be a federal court litigator, and I can tell you it’s desperately needed,” House Speaker Mike Johnson, R-La., said of the bill. Sen. Todd Young, R-Ind., first introduced the bill to establish new judgeships in 2020. Last year, the policy-making body for the federal court system, the Judicial Conference of the United States, recommended the creation of several new district and court of appeals judgeships to meet increased workload demands in certain courts. “Judges work tirelessly every day to meet growing demands and resolve cases as quickly as possible, but with the volume we have and the shortage of judges we have, it just makes it a very difficult proposition,” Judge Timothy Corrigan, of the Middle District of Florida, said in a recent blog post on the website of the Administrative Office of the U.S. Courts. The blog post states that caseloads are creating delays that will erode public confidence in the judicial process, but the bill would meet many of the federal judiciary’s needs for more judges. Jordan said that as of June 30th, there were nearly 750,000 pending cases in federal district courts nationwide, with each judge handling an average of 554 filings. When asked if House Republicans would have brought the bill up if Vice President Kamala Harris had won the election, Jordan said the bill is “the right thing to do” and that almost half of the first batch of judges will come from states where both senators are Democrats, giving them a chance to provide input on those nominations before Trump makes them. But in its veto threat, the White House Office of Management and Budget said the bill would create new judgeships in states where senators have sought to hold open existing judicial vacancies. “These efforts to hold open vacancies suggest that concerns about judicial economy and caseload are not the true motivating force behind passage of the law,” the White House said. Shortly before the White House issued the veto threat, Senate Republican leader Mitch McConnell, R-Ky., said he would be curious to hear Biden’s rationale for such action. “It’s almost inconceivable that a lame-duck president could consider vetoing such an obviously prudential step for any reason other than selfish spite,” McConnell said.(CNN) — President-elect Donald Trump’s pledge to impose massive tariffs was an early warning shot to try to force the hand of allies and adversaries to come to the negotiating table on immigration and trade issues, a transition official told CNN. Trump on Monday vowed hikes in the taxes American companies must pay on goods imported from Mexico, Canada and China starting on his first day in the White House, unless those countries comply with his demands to crack down on migration and drugs flowing into the United States. “Why not? No surprises,” the transition official told CNN. “We know what works.” Trump’s posts Monday on Truth Social appeared to be the opening act in a long-promised trade war with China and North American countries – as well as the latest illustration of how the president-elect plans to force other countries to help the United States stem the flow of migrants and drugs into ports and across borders, as he often vowed on the campaign trail. It comes despite warnings that tariff hikes, if they come to fruition, could increase inflation. A Goldman Sachs analysis on Tuesday projected that Trump’s proposed hikes would increase the core personal consumption expenditures index — a key inflation gauge that excludes food and energy costs — by 0.9%. And Matt Priest, the president of the leading footwear industry trade group Footwear Distributors & Retailers of America, warned that Trump’s proposed tariffs would “directly increase costs for retailers and consumers, leading to higher prices on everyday essentials like shoes.” But it’s a strategy that stems from a belief that similar threats worked in Trump’s first term in the Oval Office, the transition official said. During those four years, Trump took a hardline — and at times, scattershot — approach toward Latin America, which was largely the source of migration to the United States. That approach included levying consequences, like sanctions, and threatening and imposing tariffs. The Goldman Sachs analysis also described Trump’s tariff announcement as “more reminiscent of the first Trump administration, when such tariffs were announced as a negotiating tactic.” Trump ultimately declined to impose some of his proposed tariffs. In 2019, tariff threats ultimately resulted in Mexico giving in to the expansion of one of the Trump administration’s key immigration policies, known as “remain in Mexico,” according to two sources familiar with the matter. The unprecedented policy required migrants to stay in Mexico for the duration of their immigration proceedings in the United States. At that time, Trump’s 25% tariff threat on Mexico was short-lived and resulted in a deal within a matter of weeks, spurred by a delegation of Mexican officials that traveled to Washington for urgent talks. Trump’s then-senior adviser Stephen Miller and top aides to then-Vice President Mike Pence led the negotiations on behalf of the United States. If the talks had dragged out, prominent business lobbies had prepared to sue the Trump administration, alleging that the tariffs were not an adequate response to a non-trade issue. CNN previously reported that Trump’s team is gaming out a similarly aggressive strategy toward Latin America that will be a crucial element to plans to deport migrants and stem migration. The president-elect is moving forward with that approach despite the leaders of neighboring countries responding that it won’t achieve Trump’s stated goals, and would trigger a mutually destructive trade war. Mexican President Claudia Sheinbaum said at a news conference Tuesday that “neither threats nor tariffs will solve the issue of migration or drug consumption.” “Imposing one tariff would mean another comes in response, continuing like this until we put shared companies at risk,” she said. “For example, some of the largest exporters from Mexico to the United States are General Motors, Stellantis and Ford Motor Company, which arrived in Mexico 80 years ago,” Sheinbaum said. “Why impose a tax that puts them at risk? It’s unacceptable and would cause inflation and job losses in Mexico and the United States.” The timing of Trump’s social media posts might have been a surprise, but their content was not. On the campaign trail, he frequently pledged to use tariffs as a negotiating tool to bend China and North American countries’ policies to his will. His advisers have acknowledged privately that tariffs could be more urgently slapped on Canada and Mexico, as Trump seeks to fulfill his campaign pledge to renegotiate his own free trade agreement. In July, Canada implemented a 3% tax on the profits of large foreign technology companies operating in the country — a move that both President Joe Biden’s outgoing administration and the incoming Trump team view as discriminatory and in violation of a 2018 trade deal between the United States, Canada and Mexico. During Trump’s first term, the three countries spent more than a year hammering out that deal — the US-Mexico-Canada Agreement — to replace the North American Free Trade Agreement, which went into force in 1994. The new deal requires all three countries to renew it by July 1, 2026, to keep it in force — and Trump’s team is expected to call for renegotiating parts of the deal. Advisers see the new tariff threat as a way to build leverage for Trump going into those talks. Trump telegraphed that approach in an October speech at the Detroit Economic Club, where he said that upon taking office, he would “formally notify Mexico and Canada of my intention to invoke the six-year renegotiation provision of the USMCA that I put in.” Trump is said to want to open trade negotiations with Canada as quickly as possible after taking office. Howard Lutnick — the co-chair of Trump’s transition effort and his pick for Commerce secretary — said in a CNBC interview before the election that “of course” tariffs are a “bargaining chip,” and would help remove barriers to American-made goods in other countries. “This is just negotiating,” he said. But Lutnick added that Trump wouldn’t seek to slap price-raising tariffs on goods that aren’t made in the United States. “Do we make a lot of money on tariffs? Or we bring productivity here and we drive up our workers here?” Lutnick said. “So it’s a win-win scenario.” CNN’s Matt Egan and David Goldman contributed to this report. The-CNN-Wire TM & © 2024 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
ESTERO, Fla. (AP) — Kaden Cooper led Louisiana Tech with 16 points, and Daniel Batcho and Amaree Abram made key free throws in the closing seconds as the Bulldogs defeated Richmond 65-62 on Tuesday. Cooper added nine rebounds and four steals for the Bulldogs (6-0). Batcho scored 13 points, going 4 of 6 and 5 of 7 from the free-throw line. Abram shot 3 for 13 (2 for 7 from 3-point range) and 4 of 4 from the free-throw line to finish with 12 points, while adding six rebounds. Delonnie Hunt finished with 26 points and three steals for the Spiders (3-4). Abram scored eight points in the first half and Louisiana Tech went into halftime trailing 35-27. Sean Newman Jr. scored a team-high 12 points for Louisiana Tech in the second half. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .‘No, it doesn’t pass pub test’: Mali backtracks on contentious job adSuspect in the killing of UnitedHealthcare’s CEO struggles, shouts while entering courthouse
Turkish Airlines to Begin Operations at The New Terminal One at JFK and Unveil World-Class Lounge
Cooper, Batcho lead Louisiana Tech past Richmond 65-62
